Teleflex (TFX) AI Stock Analysis

• Market Cap: $5.50B
• Dividend Yield: 1.09%
• Average Volume (3M): 708.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.53
• Revenue Growth: 5.43%
• EPS Growth: -245.18%
• Country: US
• Employees: 14,100
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 3.67
• Shares Outstanding: 44,194,410
• 10 Day Avg. Volume: 1,009,023
• 30 Day Avg. Volume: 708,344
• PEG Ratio: -1.49
• Price to Book (P/B): 1.95
• Price to Sales (P/S): 2.74
• P/FCF Ratio: 16.37
• Enterprise Value/Market Cap: 1.40
• Enterprise Value/Revenue: 2.42
• Enterprise Value/Gross Profit: 4.51
• Enterprise Value/Ebitda: 132.90
• 1Y Price Target: $137.20
• Price Target Upside: 12.19% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 7
• EPS Forecast (FY): 14.1
• Revenue Forecast (FY): $3.31B

• Rating: 68 Neutral
• Price Target: $143.00 ▲(16.94% Upside)

Teleflex's overall stock score is driven by strong technical indicators and positive corporate events, which are offset by financial performance challenges and valuation concerns. The company's strategic moves, such as business sales and share repurchases, enhance its growth potential, but profitability issues need to be addressed.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Teleflex's products, supporting long-term business expansion and market presence.

Strategic Divestitures

The divestiture allows Teleflex to streamline operations and focus on core growth areas, potentially enhancing profitability and strategic focus.

Share Repurchase Program

The share repurchase program reflects confidence in the company's financial health and can enhance shareholder value over the long term.

Negative Factors

Profitability Challenges

Negative profit margins indicate operational inefficiencies, which could hinder the company's ability to reinvest and grow sustainably.

Declining Free Cash Flow

Reduced free cash flow growth limits the company's ability to fund new projects and investments, potentially impacting long-term growth.

Margin Pressure

Margin pressure from tariffs and foreign exchange rates can erode profitability, affecting the company's competitive pricing and investment capacity.

Teleflex Business Overview & Revenue Model

Company Description

Teleflex Incorporated (NYSE: TFX) is a global provider of medical technologies designed to enhance the health and quality of life of patients. The company operates in various sectors, including vascular access, anesthesia, respiratory care, urology, and surgical instruments. Teleflex offers a diverse range of products, including catheters, surgical devices, and specialty tools that address various medical needs, aiming to improve patient outcomes and streamline healthcare processes.

How the Company Makes Money

Teleflex generates revenue primarily through the sale of its medical devices and technologies across multiple healthcare sectors. The company's key revenue streams include its vascular access products, which are critical for various medical procedures, as well as its anesthesia and respiratory care offerings. Teleflex also benefits from partnerships with healthcare providers and institutions, enabling it to gain insights into market needs and drive innovation. Additionally, the company invests in research and development to expand its product portfolio, which further enhances its revenue potential. Sales are made through direct sales teams and distributors, ensuring broad market access.

Teleflex Financial Statement Overview

Summary

Teleflex shows mixed financial performance. Revenue growth is positive at 4.89%, but profitability metrics are weak with a negative net profit margin of -10.28%. The balance sheet is strong with low leverage, but the negative ROE is concerning. Cash flow generation is adequate, but declining free cash flow growth poses a risk.

Income Statement

Teleflex's income statement shows a mixed performance. The company has experienced a positive revenue growth rate of 4.89% in the TTM, indicating a healthy top-line expansion. However, the net profit margin has turned negative at -10.28% in the TTM, primarily due to a significant net loss. The gross profit margin remains stable at around 53.67%, but the decline in EBIT and EBITDA margins suggests challenges in operational efficiency.

Balance Sheet

Teleflex's balance sheet reflects a solid equity position with a low debt-to-equity ratio of 0.052 in the TTM, indicating low financial leverage. However, the return on equity has turned negative at -7.98%, highlighting profitability challenges. The equity ratio remains strong, suggesting a stable capital structure.

Cash Flow

The cash flow statement shows a decline in free cash flow growth by -16.69% in the TTM, which could impact future investments. The operating cash flow to net income ratio is 0.51, indicating moderate cash generation relative to net income. The free cash flow to net income ratio is high at 0.92, suggesting efficient cash conversion despite the net loss.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.19B	3.05B	2.97B	2.79B	2.81B	2.54B
Gross Profit	1.71B	1.70B	1.65B	1.53B	1.55B	1.32B
EBITDA	58.11M	433.62M	761.21M	730.77M	853.80M	651.48M
Net Income	-327.97M	69.67M	356.33M	363.14M	485.37M	335.32M
Balance Sheet
Total Assets	7.87B	7.10B	7.53B	6.93B	6.87B	7.15B
Cash, Cash Equivalents and Short-Term Investments	354.00M	306.16M	222.85M	292.03M	445.08M	375.88M
Total Debt	2.77B	1.76B	1.93B	1.83B	1.97B	2.56B
Total Liabilities	4.05B	2.82B	3.09B	2.91B	3.12B	3.82B
Stockholders Equity	3.82B	4.28B	4.44B	4.02B	3.75B	3.34B
Cash Flow
Free Cash Flow	264.33M	509.31M	419.20M	262.95M	579.80M	345.71M
Operating Cash Flow	390.94M	635.74M	510.64M	342.14M	651.42M	436.41M
Investing Cash Flow	-849.87M	-99.36M	-621.23M	-257.94M	156.74M	-837.78M
Financing Cash Flow	554.03M	-421.93M	38.54M	-217.51M	-715.82M	455.16M

Teleflex Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 122.29
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TFX, the sentiment is Positive. The current price of 122.29 is above the 20-day moving average (MA) of 121.95, above the 50-day MA of 120.17, and below the 200-day MA of 123.43, indicating a neutral trend. The MACD of 1.98 indicates Positive momentum. The RSI at 51.83 is Neutral, neither overbought nor oversold. The STOCH value of 13.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TFX.

Teleflex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LMAT	75 Outperform	$1.92B	36.13	15.02%	0.95%	13.07%	27.98%
HAE	70 Outperform	$3.76B	23.44	19.47%	―	-2.45%	41.50%
MMSI	68 Neutral	$5.21B	44.85	8.30%	―	11.49%	-2.89%
TFX	68 Neutral	$5.50B	-16.62	-7.90%	1.09%	5.43%	-245.18%
ICUI	61 Neutral	$3.66B	-474.43	-0.35%	―	-0.81%	93.27%
BLCO	55 Neutral	$5.99B	-19.66	-4.69%	―	6.23%	17.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Teleflex Corporate Events

Teleflex Announces $2.03 Billion Business Sale Agreements

On December 9, 2025, Teleflex announced agreements to sell its Acute Care, Interventional Urology, and Original Equipment Manufacturing (OEM) businesses for a total of $2.03 billion in cash. The transactions are expected to close in the second half of 2026, subject to regulatory approvals. The proceeds will be used for share repurchases and debt reduction, enhancing Teleflex’s financial flexibility and allowing it to focus on its core critical care and high acuity hospital markets. The company’s Board of Directors has also authorized a $1 billion share repurchase program, reflecting confidence in Teleflex’s strategic direction and growth potential.

Teleflex Reports Strong Q3 2025 Financial Results

Teleflex announced its financial results for the third quarter ending September 28, 2025, reporting a 19.4% increase in GAAP revenue compared to the previous year. Despite a decrease in order rates for its intra-aortic balloon pump portfolio, the company exceeded expectations in adjusted operating margin and earnings per share. Teleflex is also narrowing its revenue growth guidance for 2025 and continues to focus on its strategy to drive shareholder value, including the potential sale of its NewCo division.